Drug Website, Directory & Medical Information

Ethosuximide not supported for IBS pain management 20 Jan 2026
The T-type calcium channel blocker ethosuximide has shown limited benefit in the treatment of irritable bowel syndrome (IBS)-related abdominal pain in a proof-of-concept study.

Low-dose olanzapine as good as megestrol acetate for cancer anorexia–cachexia syndrome

20 Jan 2026

Does erythromycin/clindamycin resistance predict mortality in MSSA bacteremia?

20 Jan 2026

Use of sacituzumab govitecan safe, efficacious in pretreated mBC

20 Jan 2026

‘Difficult’ patients nag healthcare providers

20 Jan 2026

Genetic predisposition to higher BMI ups mortality risk in breast cancer survivors

19 Jan 2026

Metformin prevents ACS-induced maternal hyperglycaemia, neonatal hypoglycaemia

19 Jan 2026

5-year data back omission of sentinel lymph node biopsy in early-stage breast cancer

19 Jan 2026

Melatonin may reduce delirium burden in children admitted to ICU

19 Jan 2026

Sacituzumab govitecan proves real-world survival benefits in metastatic breast cancer

19 Jan 2026

PCSM model predicts long-term mortality risk from prostate cancer

19 Jan 2026

Diabetes as Stage 2 CKM: Why Cardiologists Need to Intervene Earlier 18 Jan 2026;
Cardiovascular disease (CVD) continues to be the primary cause of mortality among individuals with diabetes, demonstrating the complex metabolic, renal, and vascular relationships that define the cardio-kidney-metabolic (CKM) continuum. As Malaysia experiences increasing prevalence of obesity and type 2 diabetes (T2D), the burden of cardiovascular (CV) complications continues to rise. This highlights the necessity for a novel clinical perspective, one that acknowledges metabolic dysfunction as an integral aspect of a systemic disorder, thus necessitating urgent, coordinated intervention. In this second of a series of articles championing awareness on the CKM concept, Datin Dr Ong Mei Lin explains the necessity for cardiologists to assume a more proactive role in managing diabetes at CKM Stage 2 and discusses how evidence-based treatments, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as semaglutide, can influence long-term CV outcomes.